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Abstract 
Background: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with diabetes 
mellitus (DM). To identify the most effective treatment for CVD, it is paramount to understand the mechanism behind 
cardioprotective therapies. Although metformin has been shown to reduce CVD in Type‑2 DM clinical trials, the 
underlying mechanism remains unexplored. CD34+ cell‑based therapies offer a new treatment approach to CVD. The 
aim of this study was to investigate the effect of metformin on the angiogenic properties of CD34+ cells under condi‑
tions mimicking acute myocardial infarction in diabetes.
Methods: CD34+ cells were cultured in 5.5 or 16.5 mmol/L glucose ± 0.01 mmol/L metformin and then addition‑
ally ± 4 % hypoxia. The paracrine function of CD34+ cell‑derived conditioned medium was assessed by measuring 
pro‑inflammatory cytokines, vascular endothelial growth factor A (VEGFA), and using an in vitro tube formation assay 
for angiogenesis. Also, mRNA of CD34+ cells was assayed by microarray and genes of interest were validated by 
qRT‑PCR.
Results: Metformin increased in vitro angiogenesis under hyperglycemia–hypoxia and augmented the expression of 
VEGFA. It also reduced the angiogenic‑inhibitors, chemokine (C–X–C motif ) ligand 10 (CXCL10) and tissue inhibitor of 
metalloproteinase 1 (TIMP1) mRNAs, which were upregulated under hyperglycemia–hypoxia. In addition metformin, 
increased expression of STEAP family member 4 (STEAP4) under euglycemia, indicating an anti‑inflammatory effect.
Conclusions: Metformin has a dual effect by simultaneously increasing VEGFA and reducing CXCL10 and TIMP1 in 
CD34+ cells in a model of the diabetic state combined with hypoxia. Therefore, these angiogenic inhibitors are prom‑
ising therapeutic targets for CVD in diabetic patients. Moreover, our data are commensurate with a vascular protective 
effect of metformin and add to the understanding of underlying mechanisms.
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Background
Cardiovascular disease (CVD) remains the major cause 
of morbidity and mortality worldwide [1]. The increased 
risk of CVD in patients with diabetes is well established, 
and their disease progression is greater than for non-dia-
betic patients despite similar interventions [2]. CVD is 
the major cause of mortality in diabetic patients account-
ing for more than 50 % of all fatalities [2]. Furthermore, 
the outcome of CVD interventions in patients with dia-
betes is much worse in comparison with non-diabetic 
individuals [3, 4]. Impaired angiogenesis is an important 
factor leading to the development of diabetes associated 
CVD [5, 6]. Thus, there is an increasing demand for an 
investigation of new therapeutic targets and treatment 
approaches directed at restoring angiogenesis in diabetic 
CVD cases.
CD34+ cells alone or as part of bone marrow aspirate 
have been used as novel stem cell therapies in the treat-
ment of acute myocardial infarction (MI) or heart fail-
ure with beneficial effect [7]. A study in SCID mice after 
experimental MI showed that the primary mode of action 
of CD34+ cells is paracrine [8]. Paracrine secretion and 
tissue repair were reported to be impaired in CD34+ cells 
from diabetic patients in comparison to non-diabetic or 
healthy volunteers [9–11]. Patients with diabetes have 
increased circulating levels of inflammatory markers 
including tumor necrosis factor-α (TNF-α), interleukin-6 
(IL-6), and chemokine (C–C motif ) ligand 2 (CCL2) [12]. 
In addition, increased levels of inflammatory markers 
predict cardiovascular risk in diabetic patients [13].
Metformin is the anti-diabetic drug that reduced CVD 
in Type-2 diabetes mellitus (DM) clinical trial (UKPDS) 
[14]. Although clinical studies provide plausible evidence 
that metformin improves endothelial function [15–17], 
the underlying mechanism is not clearly understood. 
In the current proof of concept study, we used human 
CD34+ cells to understand the beneficial effect of met-
formin on angiogenesis at 3  h of hypoxia, as this is a 
therapeutic window in the management of acute myocar-
dial infarction. As umbilical cord blood (UCB) is a non-
invasive source of CD34+ cells with a higher number of 
primitive CD34+ cells than bone marrow we used UCB 
derived CD34+ cells in our experiments [18, 19].
We reasoned that understanding the cardioprotective 
mechanism behind metformin therapy will underpin the 
identification of potential new therapeutic targets and 




Human umbilical cord blood was collected in 250  mL 
blood collection bags (Macropharma, Tourcoing, France) 
for the isolation of CD34+ cells. Human umbilical cords 
were collected and preserved in 50  mL conservation 
buffer containing Dulbecco’s phosphate buffer saline 
without Ca+2 and Mg+2, 200  U/mL penicillin, 200  µg/
mL streptomycin, and 2.5 µg/mL fungizone (Gibco, Life 
Technologies, Paisley, UK).
The study was approved by NHS Health Research 
Authority, NRES Committee North East-Sunderland, 
UK (12/NE/0044) and subjects gave informed written 
consent.
CD34+ cell culture
CD34+ cells were isolated from three different UCB col-
lections per condition (10 conditions studied) using 
Lymph prep protocol and CD34 Microbeads separation 
according to the manufacturer’s instructions (Miltenyi 
Biotic Inc., Bergisch Gladbach, Germany). The purity 
of isolated CD34+ cells was assessed by flow cytometry 
(FACSCanto II, BD, Bioscience, San Jose, CA). All sam-
ples showed purity >95 %.
Approximately 1  ×  106 CD34+ cells per condition 
were cultured in M199 medium supplemented with 
2.0  mmol/L l-glutamate, 100  Units/mL penicillin, 
100  μg/mL streptomycin, 2.5  µg/mL fungizone (Gibco, 
Life Technologies, Paisley, UK), 0.25  % (v/v) human 
serum albumin (Octapharma, Manchester, UK), 15 mM 
HEPES, 1.35  g/L NaHCO3 (GE Healthcare, Little Chal-
font, UK), 100  ng/mL Flt3-L, and 100  ng/mL stem cell 
factor (PerproTech, Rocky Hill, NJ, USA).
CD34+ cells were incubated in a culture medium with 
5.5  mmol/L (euglycemia) or 16.5  mmol/L (hyperglyce-
mia) glucose concentrations (Sigma-Aldrich, Dorset, 
UK). Glucose at 16.5  mmol/L simulates a diabetic state 
but did not impair cellular growth, whereas increased the 
expression of endothelial adhesion molecules, consist-
ent with hyperglycemia-mediated vascular inflammation 
[20–22]. The cells were simultaneously incubated in the 
presence or absence of 0.01 mmol/L metformin (Sigma-
Aldrich, Dorset, UK) for 24  h. The metformin concen-
tration used was selected according to the peak plasma 
concentration and metformin pharmacokinetics reported 
earlier in diabetic patients [23]. Subsequently, cells were 
subjected additionally to 4  % hypoxia (Heracell™ 150i, 
ThermoScientific) for 3 h to simulate cellular and molec-
ular responses following ischemia [24].
Meso scale discovery (MSD) assay
The culture medium was collected from 5 × 105 CD34+ 
cells exposed to the above mentioned conditions and 
assayed using K15025C human Pro-inflammatory II 
4-Plex, K151A0H Custom V-PLEX Human Biomark-
ers (Meso Scale Discovery, Rockville, MD) in accord-
ance with the manufacturer protocol. Plates were read 
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with MSD Sector Imager 2400 and data were analyzed 
by MSD Discovery Workbench version 2.0 software. 
The data were normalized against the complete culture 
medium, and three samples were processed in duplicates.
HUVEC cultures
HUVEC were harvested from three independent 
umbilical cords as previously described by us [21]. All 
experiments were performed at passage two and 80  % 
confluency.
In vitro Matrigel tube formation assay
HUVEC (2.0  ×  104 cells) were serum starved over-
night in M199 complete medium with 0.25  % FBS. An 
in  vitro tube formation assay was performed as previ-
ously described with minor modifications [25]. EBM-2 
medium containing 14 µmol/L sunitinib malate (VEGFA 
inhibitor, Sigma-Aldrich, Dorset, UK) was used as a neg-
ative control, and this concentration showed no toxicity 
in HUVEC cell cultures as illustrated in Additional file 1: 
Figure S1. Subsequently, the cells were incubated at 37 °C 
and 5 % CO2 (OkoLab, NA, Italy) for 24 h in a chamber 
that was connected to a camera (Hamamatsu Orca ER, 
Hamamatsu City, Japan). Tube formation was examined 
by phase-contrast microscopy (Nikon Eclipse Tie, Tokyo, 
Japan) using software based autofocus (NIS Elements 
V4.0, Nikon, Tokyo, Japan). Images were acquired every 
hour. All conditions in each experiment were assessed 
in duplicate, and tube length was measured as the mean 
summed length of capillary-like structures in 2 wells. 
Three independent experiments were performed for each 
condition. The tube length was measured using Adobe 
Acrobat Professional version 8 software by measuring 
long tubes first and then the small branches to cover the 
whole image. The analysis was conducted blinded.
Total RNA extraction
Total RNA from CD34+ cells was extracted using the RNe-
asy Mini Kit (QIAGEN, Hilden, Germany) according to 
the manufacturer’s instructions. The cell lysates from three 
different CD34+ cultures per condition were pooled before 
proceeding to an RNeasy Mini spin column. On-column 
DNase digestion with RNase-Free DNase set (QIAGEN) 
was performed. The quality and quantity of RNA was 
assessed using a NanoDrop 2000c Spectrophotometer 
(Thermo Scientific, Wilmington, DE, USA). The integrity 
of RNA samples was assessed by using Agilent 2100 Bio-
analyzer (Santa Clara, CA, USA) yielding high RNA Integ-
rity Numbers (RIN) between 7.0 and 9.7.
Microarray experiments and gene expression analysis
Microarray experiments were performed using Affym-
etrix (Santa Clara, CA, USA) Human Gene 1.0 ST arrays 
according to manufacturer’s instructions with minor 
modifications [21, 26]. Two technical replicates were 
hybridized for each experimental condition resulting in a 
total of 20 microarray experiments.
Affymetrix CEL files were imported to Partek Genomic 
Suite version 6.6 (Partek Inc., MO, USA). The data were 
normalized using Robust Multichip Average (RMA) 
normalization. Principal component analysis (PCA) was 
performed on all probes to visualize high-dimensional 
data. By default, expression values were filtered for sta-
tistical significance using Benjamini and Hochberg’s False 
Discovery Rate (FDR), with an FDR-unadjusted p value 
<0.05. ANOVA was performed using the commonly 
employed p values <0.05 and cut off fold change (FC) 
≥1.5 as described by Peart et al. [27] and Raouf et al. [28].
Two-dimensional average linkage hierarchical cluster-
ing was performed for the differentially expressed genes 
using Spearman’s correlation as a similarity matrix. The 
microarray data generated in this study are in compli-
ance with MIAME (http://www.mged.org/Workgroups/
MIAME/miame.html) guidelines. The complete dataset 
and associated experimental information were submitted 
to NCBI’s Gene Expression Omnibus (GEO) and were 
accessible through accession number GSE46262. Inge-
nuity pathway analysis (IPA) software version 9 (Inge-
nuity, Redwood City, CA, USA) was employed to enable 
exploring the Canonical Pathways that may be increased 
or decreased based on activation or inhibition of mol-
ecules within that pathway. Additionally, IPA assisted in 
detecting the interactive molecular and cellular functions 
affected in each condition.
Quantitative RT‑PCR
Approximately 100  ng of total RNA from each sam-
ple was converted to cDNA using SuperScript VILO™ 
cDNA Synthesis Kit (Life Technologies, Paisley, UK) in 
a final volume of 20 μL. The cDNA product was quanti-
fied by hydrolysis probe real-time PCR performed with 
TaqMan® Universal Master Mix II and assayed on a 
7900HT Fast Real-time PCR system (Life Technologies) 
according to the manufacturer’s recommended condi-
tions. Expression of the following genes were determined 
using the TaqMan gene expression assays (Life Technolo-
gies): CCL2: Hs00234140_m1, CCL5: Hs00174575_m1, 
C–X–C motif chemokine 10 (CXCL10): Hs01124251_
g1, hepatocyte growth factor (HGF): Hs00900070_m1, 
IL-1α: Hs00174092_m1, IL-6: Hs00985639_m1, IL-
8: Hs00174103_m1, tissue metallopeptidase inhibi-
tor 1 (TIMP1): Hs00171558_m1, selectin P (SELP): 
Hs00927900_m1. All samples were run in triplicate, and 
average values were calculated. Three independent reverse 
transcriptions were tested for each gene. The Comparative 
Ct method (ΔΔCt) was used to quantify expression of the 
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target genes, which were normalized to the endogenous 
control gene for the large ribosomal protein P0 (RPLP0) 
[21] (Catalog number 432631, Life Technologies).
Statistical analysis
Results are presented as mean  ±  SEM, and statistical 
analysis was performed using one-way ANOVA followed 
by post hoc analysis using Fisher’s least significant dif-
ference (LSD) test for the in  vitro Matrigel tube forma-
tion assay, qRT-PCR, and MSD assay. Calculations were 
performed using IBM SPSS software version 21.0 (SPSS 
Inc, NY). A p value <0.05 was considered statistically 
significant.
Results
Secretion of pro‑inflammatory and pro‑angiogenic 
cytokines by CD34+ cells
Measured concentrations of the pro-inflammatory 
cytokines IL-1β, IL-6, IL-8, and TNF-α; were very low 
in conditioned medium (CM) of CD34+ cells under all 
conditions studied. However, the pro-angiogenic fac-
tor VEGFA was found to be significantly increased in 
CM collected from CD34+ cells treated with hypergly-
cemia (2.0-fold, p  <  0.001) versus euglycemia, whereas 
no change was observed under hyperglycemia com-
bined with hypoxia for 3  h versus hyperglycemia. The 
CM from CD34+ cells treated with metformin displayed 
augmented levels of VEGFA either under euglycemia 
(1.6-fold, p = 0.008), euglycemia combined with hypoxia 
(1.4-fold, p = 0.037), and hyperglycemia combined with 
hypoxia (1.2-fold, p  =  0.037) compared with the met-
formin-untreated condition (Fig. 1).
The effect of metformin on in vitro angiogenic function 
of CD34+ cell‑derived CM
Metformin significantly increased tube formation by 
30.7 % (p = 0.04) in HUVEC incubated with CD34+ CM 
derived from cells treated with hyperglycemia–hypoxia 
compared with the condition without metformin (Fig. 2a 
highlighted with red and b). However, under other condi-
tions metformin did not cause any significant increase in 
tube formation.
Metformin drives a gene expression profile consistent 
with an anti‑inflammatory action under euglycemia 
and euglycemia‑hypoxia
The transcriptomic analysis of CD34+ cells showed 
that 313 genes passed the cutoff FC of 1.5 and p value 
<0.05 under euglycemia and metformin compared to 
euglycemia alone. The top associated molecular and 
cellular functions predicted using IPA were inflam-
matory response (p  =  1.52E−06) and binding of EC 
(p = 1.56E−06), which were inhibited by metformin. The 
corresponding downregulated genes are highlighted in 
Table 1.
One hundred genes were differentially expressed in 
CD34+ cells (cutoff FC of 1.5 and p value <0.05) under 
euglycemia and hypoxia compared to euglycemia alone. 
The top molecular and cellular functions affected as pre-
dicted by IPA are reported in Additional file 1: Table S1. 
Metallothionein 2A (MT2A) was upregulated (1.7-fold, 
p = 4.70E−03) under hypoxia which was previously indi-
cated as one of hypoxia inducible genes [29].
Metformin treatment of CD34+ cells exposed to eug-
lycemia and hypoxia caused differential expression of 21 
genes compared with the metformin-untreated condi-
tion. The top related molecular functions predicted by 
IPA were: cell death/survival (p = 7.23E−04), and cellular 
growth/proliferation (p  =  7.23E−04). Genes associated 
with these functions were IL-5 (1.52-fold, p = 7.05E−03), 
serine peptidase inhibitor, Kazal type 7 (putative) 
(SPINK7, 1.60-fold, p  =  1.48E−02), and transducer of 
ERBB2, 2 (TOB2, −1.53-fold, p = 4.62E−02).
Metformin had no effect on inflammatory response, 
cell movement, or adhesion under euglycemia-hypoxia as 
demonstrated in Additional file 1: Figure S2.
Metformin drives a gene expression profile 
consistent with improved cell survival in CD34+ cells 
under hyperglycemia
Analysis of microarray data revealed that 370 genes 
passed the cutoff FC of 1.5 and p value <0.05 under 
Fig. 1 Expression of pro‑angiogenic factor VEGFA in CD34+ cell‑
derived conditioned media. The levels of VEGFA were assayed in three 
independent biological replicates using the MSD technique. Results 
are presented as ±SEM and were statistically analyzed using one‑way 
ANOVA followed by Fisher’s LSD test. Data for effects of hypoxia and 
hyperglycemia were compared with control (5.5 mmol/L), and data 
for cells treated with metformin were compared with the correspond‑
ing metformin‑untreated condition. *P < 0.05, **P < 0.01, ***P < 0.001
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Fig. 2 Effect of CM from CD34+ cells exposed to different conditions on in vitro angiogenic assays. a HUVEC were plated on Matrigel with CM 
from 2.0 × 105 CD34+ cells treated with euglycemia, euglycemia and hypoxia, hyperglycemia or hyperglycemia and hypoxia in the presence and 
absence of metformin. EBM‑2 medium containing the VEGF inhibitor sunitinib (14 µmol/L) was used as a negative control for the assay. The high-
lighted image shows the greatest tube length, which was achieved in HUVEC incubated with CM‑derived from CD34+ cells treated with hypergly‑
cemia and hypoxia in the presence of metformin. b Tube length at 6 h was expressed as a percentage of the tube length of HUVEC treated with 
5.5 mmol/L glucose CM (n = 3); *P < 0.05 compared pairwise, i.e., condition with metformin versus metformin‑untreated condition
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hyperglycemia versus euglycemia. Approximately 35  % 
of the genes were upregulated, and 65 % were downreg-
ulated. The uppermost 30 differentially expressed genes 
are listed in Additional file 1: Table S2. The top molecular 
functions predicated by IPA were cell to cell signaling and 
interaction (p = 1.80E−17), cellular growth/proliferation 
(p = 1.21E−12), inflammatory response (p = 1.59E−12), 
cellular movement (p =  2.60E−11) which were all pre-
dicted to be inhibited (Additional file  1: Table S3). The 
main canonical pathways affected were atherosclero-
sis signaling (p = 3.2E−07), T helper cell differentiation 
(p = 6.6E−04), IL-6 signaling (p = 2.1E−03) (Additional 
file 1: Table S4).
Metformin treatment of CD34+ cells under hyper-
glycemia led to differential expression of 65 genes com-
pared with hyperglycemia alone. Approximately 40  % 
of the genes were upregulated, and 60  % were down-
regulated. The top differentially expressed genes are 
listed in Additional file  1: Table S5. The top associated 
molecular functions predicted by IPA were cell death/
survival (p  =  1.29E−02), and cell proliferation/growth 
(p  =  3.25E−03). The genes attributed to cell death/
survival were killer cell immunoglobulin-like recep-
tor, two domains, short cytoplasmic tail, 5 (KIR2DS5) 
1.75-fold, p = 2.27E−02, ubiquitin specific peptidase 18 
(USP18) 1.63-fold, p  =  3.10E−03. The genes related to 
Table 1 Anti-inflammatory genes affected by metformin in CD34+ cells under euglycemia identified by IPA
The gene list was created by importing Affymetrix .CEL files to Partek Genomic Suite version 6.6. The data were Robust Multichip Average (RMA) normalized. The list 
of differentially expressed genes was generated using one-way ANOVA, applying FDR-unadjusted p value <0.05 with a fold change cutoff of 1.5. Then the list of anti-
inflammatory genes was created by IPA software according to the associated molecular and cellular functions
a Genes assessed by cytokine assays for paracrine secretion
Gene name Gene symbol FC Family
Asp (abnormal spindle) homolog, microcephaly associated (Drosophila) ASPM −1.52 Other
Complement component 3 C3 −1.51 Peptidase
Chemokine (C–C motif ) ligand 2 CCL2 −1.68 Cytokine
Chemokine (C–C motif ) ligand 5 CCL5 −1.81 Cytokine
CD24 molecule CD24 −1.61 Other
Centromere protein E, 312 kDa CENPE −1.51 Other
C‑type lectin domain family 2, member D CLEC2D −1.59 Transmembrane receptor
Chymase 1, mast cell CMA1 1.58 Peptidase
Cathepsin L1 CTSL1 −1.50 Peptidase
Glomulin, FKBP associated protein GLMN −1.62 Other
Heparanase HPSE −1.60 Enzyme
Immunoglobulin heavy constant epsilon IGHE 1.57 Other
Interleukin 18 receptor 1 IL‑18R1 −1.56 Transmembrane receptor
Interleukin 1, alpha IL‑1α −3.66 Cytokine
Interleukin 26 IL‑26 1.53 Cytokine
Interleukin 36, gamma IL‑1F9 −1.56 Cytokine
Interleukin 6 (interferon, beta 2)a IL‑6 −2.21 Cytokine
Interleukin 8a IL‑8 −1.55 Cytokine
Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) ITGB3 −1.51 Transmembrane receptor
Met proto‑oncogene (hepatocyte growth factor receptor) MET −1.63 Kinase
Antigen identified by monoclonal antibody Ki‑67 MKI67 −1.61 Other
Nuclear receptor corepressor 2 NCOR2 1.77 Transcription regulator
Pro‑platelet basic protein (chemokine (C–X–C motif ) ligand 7) PPBP −1.69 Cytokine
S100 calcium binding protein A8 S100A8 1.71 Other
Serpin peptidase inhibitor, clade B (ovalbumin), member 2 SERPINB2 −4.62 Other
Sclerostin SOST 1.56 Other
SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae) SPC25 −1.50 Other
STEAP family member 4 STEAP4 1.90 Oxidoreductase
Thrombospondin 1 THBS1 −1.50 Other
Tumour necrosis factor, alpha‑induced protein 6a TNFAIP6 −2.36 Other
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cell proliferation/growth were epithelial cell adhesion 
molecule (EPCAM) −2.06-fold, p  =  9.93E−03, USP18, 
and hydroxy-delta-5-steroid dehydrogenase, 3 beta- 
and steroid delta-isomerase 1 (HSD3B1) −1.64-fold, 
p = 2.73E−02.
It is of particular interest that vascular endothelial 
growth factor receptor-2 (VEGFR-2) was downregu-
lated under hyperglycemia in a dose-dependent manner 
(−1.95-fold, p = 3.23E−04) for 16.5 mmol/L and (−3.0-
fold, p = 5.3E−06) for 25 mmol/L and not improved by 
metformin treatment (Additional file 1: Table S3).
Metformin drives a gene expression profile 
consistent with pro‑angiogenic action in CD34+ cells 
under hyperglycemia with hypoxia
We identified 1006 differentially expressed genes in cells 
under hyperglycemia exposed to hypoxia compared 
with hyperglycemia. 52 % of the genes were upregulated 
whereas 48  % were downregulated. The top 20 signifi-
cantly differentially expressed genes are listed in Table 2. 
The most affected functions predicted by IPA were cell 
cycle (p = 1.95E−19), cellular movement (p = 2.03E−09), 
and cellular proliferation (p  =  1.39E−07), which were 
predicted to be activated, whereas chemotaxis of vascular 
endothelial cells (p  =  6.44E−03) was predicted to be 
inhibited. Downregulation of pro-angiogenic cytokines 
IL-8 (−2.12-fold, p  =  3.55E−04) and HGF (−1.64-fold, 
p  =  2.33E−03) was detected, while upregulation of 
angiogenic inhibitors TIMP1 (2.36-fold, p =  6.34E−06), 
TIMP3 (2.15-fold, p  =  2.29E−02), and CXCL10 (1.89-
fold, p = 2.04E−02) was indicated.
Under metformin combined with hyperglycemia–
hypoxia, 317 genes were differentially expressed versus no 
metformin. Forty-two percent of the genes were upregu-
lated whereas 58 % were downregulated. The 20 most dif-
ferentially expressed genes are listed in Table 3. The most 
affected functions predicted by IPA were cellular move-
ment (p  =  3.19E−05), and DNA replication and repair 
(p  =  1.41E−04). The main canonical pathways affected 
were mitochondrial dysfunction (p  =  2.0E−03), triacyl-
glycerol biosynthesis (p  =  7.1E−03), MAPK signaling 
(p = 7.9E−03), Type 1 DM signaling (p = 9.5E−03), and 
IL-8 signaling (p = 2.3E−02) (Additional file 1: Table S6).
Furthermore, metformin downregulated the angio-
genic inhibitors TIMP1 [30] (−1.68-fold, p = 3.90E−04), 
and CXCL10 [31] (−2.01-fold, p = 1.28E−02), whilst had 
no effect on expression of pro-angiogenic factors under 
hyperglycemia–hypoxia versus no metformin.
Table 2 Top differentially expressed genes in CD34+cells induced by hyperglycemia–hypoxia for 3 h versus hyperglyce-
mia
The gene list was created by importing Affymetrix .CEL files to Partek Genomic Suite version 6.6. The data were RMA normalized. Differentially expressed gene list was 
generated using one-way ANOVA, Benjamini and FDR-unadjusted p value <0.05 with a fold change cutoff of 1.5 was applied
Gene name Gene symbol p value FC
Non‑SMC condensin I complex, subunit H NCAPH 1.46E−09 2.24
Polo‑like kinase 1 PLK1 1.54E−09 4.71
Cyclin A2 CCNA2 1.94E−09 2.57
Serine/arginine‑rich splicing factor 4 SRSF4 1.15E−08 −1.73
Protein regulator of cytokinesis 1 PRC1 1.17E−08 2.17
TIMP metallopeptidase inhibitor 3 TIMP3 1.24E−08 2.14
Lysine (K)‑specific demethylase 5D KDM5D 2.59E−08 1.86
TPX2, microtubule‑associated, homolog (Xenopus laevis) TPX2 6.63E−08 2.64
Cell division cycle 20 homolog (S. cerevisiae) CDC20 8.42E−08 3.08
Olfactory receptor, family 2, subfamily L, member 13 OR2L13 9.20E−08 −1.93
Prohibitin PHB 9.25E−08 1.99
ZW10 interactor ZWINT 9.82E−08 1.93
X‑ray repair complementing defective repair in Chinese hamster cells 2 XRCC2 1.44E−07 1.61
Brain expressed, X‑linked 4 BEX4 1.47E−07 −1.76
Protein kinase, membrane associated tyrosine/threonine 1 PKMYT1 1.61E−07 2.14
Golgin A8 family, member B GOLGA8B 1.62E−07 −1.64
Holliday junction recognition protein HJURP 1.67E−07 2.55
S100 calcium binding protein A8 S100A8 2.10E−07 −5.24
TIMP metallopeptidase inhibitor 1 TIMP1 6.34E−06 2.36
Chemokine (C–X–C motif ) ligand 10 CXCL10 2.04E−02 1.89
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Confirmation of effects of metformin on gene expression 
in CD34+ cells using qRT‑PCR
Seven pro-angiogenic factors CCL2, CCL5, HGF, IL-1a, 
IL-6, IL-8, selectin P (SELP) and two angiogenic inhibitors 
CXCL10 and TIMP1 with critical biological functions 
were validated by qRT-PCR (Additional file 1: Figure S3) 
and their results were compared to those obtained from 
the microarray experiments using the same RNA samples 
(Additional file 1: Figure S4). The qRT-PCR results were 
concordant with all gene expression changes indicated 
by the microarray data except TIMP1 which was justified 
later (Additional file 1: Table S7). Moreover, hyperglyce-
mia and metformin resulted in an increase of the mRNA 
levels of HGF (1.7-fold, p  =  0.001), and IL-6 (2.8-fold, 
p = 0.01) although this increase remained below normal 
level observed at euglycemia.
Discussion
To our knowledge, this is the first report describing the 
effect of a physiological concentration of metformin on 
the angiogenic potential of CD34+ cells. Metformin is a 
hypoglycemic agent found to have cardioprotective prop-
erties as borne by a large clinical trial [14]. It has been 
shown that metformin has a protective effect against free 
fatty acid induced apoptosis [32] and its administration 
in diabetic patients prior to stroke onset was associated 
with reduced neurological severity and improved acute-
phase therapy outcomes [33]. Moreover, metformin’s 
pleiotropic effects and cardioprotective role beyond 
glucose-lowering effect has been recently highlighted, 
encouraging implementation in prospective studies [34]. 
A recent study has shown that metformin monotherapy 
lead to an improvement in multiple clinical parameters 
and a reduction in all-cause mortality and CVD events in 
Type 2 DM patients [35] however, the underlying mecha-
nism is unclear.
In diabetic patients CD34+ cells displayed a vasorepar-
ative dysfunction due to impaired paracrine function and 
reduced sensitivity to hypoxia [10]. Whilst, the outcome 
of trials involving administration of angiogenic cytokines 
for the purpose of therapeutic angiogenesis as an alterna-
tive treatment for ischemic heart disease have been dis-
appointing [36–38].
Autologous CD34+ based stem cell therapies have been 
pioneered as an alternative treatment for CVD [39–42]. 
Therefore, we studied vasoreparative properties of 
CD34+ cells following incubation with physiological con-
centration of metformin, under conditions of hyperglyce-
mia, and/or hypoxia as a model of intervention window 
during acute myocardial infarction. Our research focused 
on the paracrine secretion of selected pro-inflammatory, 
pro-angiogenic factors and angiogenic inhibitors, which 
Table 3 Top differentially expressed genes in  CD34+ cells treated with  hyperglycemia–metformin–hypoxia for  3  h ver-
sus hyperglycemia–hypoxia
Refer to legend in Table 2
Gene name Gene symbol p value FC
Serine/arginine‑rich splicing factor 4 SRSF4 3.32E−09 1.87
Brain expressed, X‑linked 4 BEX4 1.43E−07 1.76
Dihydrouridine synthase 4‑like (S. cerevisiae) DUS4L 2.41E−07 1.60
Mitochondrial ribosomal protein S21 MRPS21 2.99E−07 1.52
Endoplasmic reticulum protein 29 ERP29 6.47E−07 −1.74
Prohibitin PHB 1.40E−06 −1.67
Chromosome 11 open reading frame 58 C11orf58 1.48E−06 1.91
NOP14 nucleolar protein homolog (yeast) NOP14 1.50E−06 1.52
Deoxynucleotidyltransferase, terminal, interacting protein 1 DNTTIP1 1.97E−06 1.91
Family with sequence similarity 98, member A FAM98A 2.03E−06 1.52
Dynactin 3 (p22) DCTN3 2.25E−06 −2.14
Solute carrier family 25, member 32 SLC25A32 2.47E−06 2.02
Heterogeneous nuclear ribonucleoprotein H3 (2H9) HNRNPH3 4.21E−06 1.72
Glycerol‑3‑phosphate acyltransferase, mitochondrial GPAM 4.31E−06 −10.76
Zinc finger protein 391 ZNF391 4.55E−06 1.59
Chromosome 11 open reading frame 51 C11orf51 4.61E−06 2.36
USO1 vesicle docking protein homolog (yeast) USO1 4.64E−06 1.55
Transducer of ERBB2, 2 TOB2 1.22E−05 4.48
TIMP metallopeptidase inhibitor 1 TIMP1 3.90E−04 −1.68
Chemokine (C–X–C motif ) ligand 10 CXCL10 1.28E−02 −2.01
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effect was functionally studied using an in  vitro tube 
formation assay. Furthermore, gene expression profil-
ing of CD34+ cells, treated under the above mentioned 
conditions, was performed focusing on pro-angiogenic 
mechanisms.
Pro‑angiogenic effect of metformin
We found that a physiological dose of metformin increased 
tube formation under the condition of hyperglycemia–
hypoxia combined. This was associated with downregu-
lation of the mRNA of the angiogenic inhibitors CXCL10 
and TIMP1 observed by microarray analysis and further 
confirmed by qRT-PCR. The discrepancy in TIMP1 results 
obtained from microarray data and qRT-PCR could be due 
to non-concordance of transcripts used in the microarray 
probe set and qRT-PCR [43]. Conversely, in the absence 
of metformin, CXCL10 and TIMP1 gene expression was 
significantly upregulated under hyperglycemia–hypoxia 
versus hyperglycemia. Our findings are concordant with 
clinical/laboratory data that demonstrated a suppression 
in angiogenesis due to an increase in angiogenic inhibi-
tors in patients with diabetes combined with an increase in 
CXCL10 and TIMP1 expression at the transcriptional and 
protein levels [44, 45].
Under conditions of euglycemia and euglycemia-
hypoxia, metformin had no measured effect on angio-
genesis as both tube formation and gene expression 
of CXCL10 and TIMP1 were unchanged. Therefore, it 
appears that metformin has no additional pro-angiogenic 
effect in the non-diabetic state. This finding is in keep-
ing with recent clinical studies, which revealed that met-
formin exhibited no effect on several surrogate markers 
of CVD in non-diabetic patients nor led to beneficial 
clinical outcome [46, 47].
In support of enhanced angiogenesis by metformin, 
we found that although the concentration of VEGFA was 
progressively increased under hyperglycemia–hypoxia it 
was further enhanced following metformin.
We confirmed in our in  vitro model, as it was shown 
in clinical studies, that hyperglycemia alone increased 
VEGFA but downregulated VEGFR-2 gene expression, 
neither of which were affected by metformin. Our find-
ings are concordant with another study in which VEGFA 
expression was found to be increased in myocardial tis-
sue of diabetic patients, whilst a decrease in VEGF recep-
tors was documented leading to downregulation of VEGF 
signal transduction [48].
Thus, although metformin further increased angiogenic 
factor, VEGFA, we have shown that the cardioprotection 
offered was predominantly by reducing angiogenic inhibi-
tors; CXCL10 and TIMP-1; rather than further increasing 
VEGFA alone. This means that the process of angiogen-
esis is under a fine balance of pro and anti-angiogenic fac-
tors to ensure tightly regulated process. Consequently, in 
the condition of diabetes combined with hypoxia it is not 
sufficient to further increase proangiogenic factors alone, 
but downregulation of inhibitors is required for altering 
the balance towards angiogenesis (Fig. 3).
Fig. 3 Summary of the effect of metformin on CD34+ cells incubated with hyperglycemia–hypoxia. CD34+ cells were treated with hyperglyce‑
mia–hypoxia versus euglycemia (a), and hyperglycemia–hypoxia with metformin versus metformin untreated‑condition (b). Green shading indicates 
downregulation, orange shading indicate upregulation and gray shading indicate unchanged gene expression. In vitro tube formation (angiogen‑
esis), green shading indicates inhibition, whereas orange shading indicates activation
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Pro‑inflammatory effect of metformin
It has been assumed that mechanism behind CD34+ cells 
based therapy for CVD is mediated by paracrine func-
tion. Thus, we hypothesized that metformin improved 
the paracrine function of CD34+ cells. However, we 
found very low protein levels of IL-1β, IL-6, and TNF-α 
with non-significantly reduced levels of IL-8 expression 
in CD34+ cell CM in all studied conditions including 
metformin. These findings can be explained by down-
regulation of genes coding for inflammatory cytokines in 
CD34+ cells under metformin and euglycemia, euglyce-
mia-hypoxia, and hyperglycemia.
We have shown that under euglycemia, metformin 
displayed an inhibitory effect on genes of pro-inflam-
matory factors CCL2, CCL5, CD226, IL-1α, IL-6, IL-8, 
and Integrin, beta 3 (ITGB3) whilst upregulating STEAP 
family member 4 (STEAP4). We thus believe that the 
anti-inflammatory action of metformin could be medi-
ated by augmenting mRNA expression of STEAP4. This 
anti-inflammatory effect has been previously demon-
strated in fibroblast-like synoviocytes by upregulation 
of STEAP4 leading to the suppression of IL-6 and IL-8 
expression [49]. In concordance with our results another 
study in smooth muscle cells, ECs, or macrophages has 
shown that a physiological dose of metformin inhibited 
the expression of IL-1β, IL-6, and IL-8 [50].
Furthermore, the same mechanism of inhibition of pro-
inflammatory cytokines was demonstrated under eugly-
cemia-hypoxia with the increase in STEAP4 expression, 
while metformin had no additional effect on those genes.
These data suggest that metformin and/or hypoxia in 
CD34+ cells are beneficial in suppressing the inflamma-
tory response. In fact, low oxygen tension in the range of 
3–5  % (hypoxia) is the preferable environment for stem 
cells (including CD34+ cells) to reside quiescent in their 
niches and maintain pluripotency with no effect on pro-
liferation [51].
In addition, we have established that TOB2 which 
acts as an anti-proliferative factor [52] was upregulated 
under hypoxic condition but was inhibited by metformin. 
TOB2 is a member of the mammalian BTG/TOB family 
of anti-proliferative proteins [53]. TOB2 were previously 
detected to be expressed in mouse embryonic stem cells 
that play a critical role in the maintenance of stem cells 
properties [52].
Similarly, under hyperglycemia and hyperglycemia–
hypoxia our transcriptome analysis demonstrated down-
regulation of pro-inflammatory and pro-angiogenic 
cytokines, chemokines and their receptors with no 
additional effect of metformin. The failure to detect the 
suppressive effect of metformin on those cells is possi-
bly due to already maximally suppressed cytokine gene 
expression.
We studied pro-inflammatory paracrine secretion by 
CD34+ cells without cell co-culture or cell expansion. 
This may be a limitation of our approach as we under-
estimate the interactions of CD34+ cells with other cells 
known to induce cytokine secretion in co-culture [54] 
or cytokine secretion from expanded CD34+ cells [55]. 
Specifically, the co-culture of CD34+ cells with HUVEC 
induced paracrine secretion of pro-inflammatory 
cytokines including IL-8, IL-6, CCL2, CCL3, and CCL4 
and angiogenesis under hypoxia [54]. Also, the co-cul-
ture of CD34+ and CD34− cells lead to enhancement 
of tube formation and cell migration compared with 
the culture of CD34+ cells alone through the cell to cell 
interactions and paracrine effects [56]. Furthermore, it 
has been reported that macrophages migrate to hypoxic 
areas that stimulate expression of pro-angiogenic such 
as VEGFA and pro-inflammatory genes in an attempt 
to repair the damage [57]. Together these data demon-
strate the significant role played by CD34− cells in inter-
action with CD34+ cells to improve tissue repair.
It is envisaged that the findings from our study will be 
validated in in vivo settings using suitable animal models 
with CXCL10 and/or TIMP1 overexpression. However, 
the current lack of appropriate animal models make it 
impossible at present to confirm the suggested mecha-
nism in vivo. Moreover, it will be of importance if these 
findings can also be proven in CD34+ cells obtained from 
diabetic patients.
Conclusions
In conclusion, vascular protection by metformin is medi-
ated by its dual effect to enhance the angiogenic potential 
of CD34+ cells by suppressing several angiogenic inhibitors 
including CXCL10 and TIMP1 whilst further increasing 
VEGFA secretion. Those angiogenic inhibitors are potential 
therapeutic targets for CVD interventions in diabetes.
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